Table 1.
Patient characteristics at study entry
| Characteristic | L (n = 13) | L + R (n = 11) | L + other (n = 34) | Overall (N = 58) | ||||
|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | No. | % | |
| Median age, years (range) | 67 (54–83) | 70 (58–84) | 71 (50–89) | 71 (50–89) | ||||
| ≥ 65 | 6 | 46 | 9 | 82 | 26 | 76 | 41 | 71 |
| Sex | ||||||||
| Male | 11 | 85 | 8 | 73 | 25 | 74 | 44 | 76 |
| Female | 2 | 15 | 3 | 27 | 9 | 26 | 14 | 24 |
| ECOG PS | ||||||||
| 0–1 | 7 | 54 | 5 | 45 | 16 | 47 | 28 | 48 |
| 2–4 | 3 | 23 | 1 | 9 | 4 | 12 | 8 | 14 |
| Missing | 3 | 23 | 5 | 45 | 14 | 41 | 22 | 38 |
| Tumor burdena | ||||||||
| High | 4 | 31 | 1 | 9 | 12 | 35 | 17 | 29 |
| Low | 1 | 8 | 5 | 45 | 13 | 38 | 19 | 33 |
| Missing | 8 | 62 | 5 | 45 | 9 | 26 | 22 | 38 |
| Bulky diseaseb | ||||||||
| Yes | 2 | 15 | 0 | 0 | 6 | 18 | 8 | 14 |
| No | 2 | 15 | 6 | 55 | 17 | 50 | 25 | 43 |
| Missing | 9 | 69 | 5 | 45 | 11 | 32 | 25 | 43 |
| Time from diagnosis to first lenalidomide dose, months | ||||||||
| Median | 58 | 47 | 46 | 49 | ||||
| Range | 15–144 | 6–105 | 4–214 | 4–214 | ||||
| Time from end of last prior antilymphoma therapy to first dose of lenalidomide, weeks | ||||||||
| Median | 0.7 | 0.3 | 0.7 | 0.7 | ||||
| Range | 0.1–3.5 | 0.1–21.7 | 0.1–12.6 | 0.1–21.7 | ||||
ECOG PS Eastern Cooperative Oncology Group performance status, L lenalidomide, L + R lenalidomide plus rituximab
aHigh tumor burden is defined as at least one lesion ≥ 5 cm in diameter or three lesions ≥ 3 cm in diameter [22]
bBulky disease is defined as at least one lesion ≥ 7 cm in the longest diameter22